Key result
BMP4 induced cardiomyocyte hypertrophy, apoptosis, and cardiac fibrosis in experimental models, and these pathological consequences were inhibited by BMP4 inhibitors noggin and DMH1.
Why the study?
Does BMP4 inhibition prevent cardiac hypertrophy, apoptosis, and fibrosis in experimental models of pathological cardiac hypertrophy?
Does BMP4 inhibition prevent cardiac hypertrophy, apoptosis, and fibrosis in experimental models of pathological cardiac hypertrophy?
BMP4 mediates pathological cardiac hypertrophy, apoptosis, and fibrosis, identifying it as a potential novel therapeutic target for heart failure.
No takes yet. Share an insight, caveat, or question.
BMP4 inhibition may mitigate experimental cardiac remodeling; leaves open translation to human heart failure therapy.
Sun et al. (2012) studied Pathological cardiac hypertrophy. BMP4 inhibitors (noggin and DMH1) was evaluated on Cardiac hypertrophy, apoptosis, and fibrosis. BMP4 induced cardiomyocyte hypertrophy, apoptosis, and cardiac fibrosis in experimental models, and these pathological consequences were inhibited by BMP4 inhibitors noggin and DMH1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: